Ketamine for Bipolar Depression: Evidence, Risks of Switching to Mania/Hypomania and Honest Limits

Direct answer: ketamine has shown rapid, short-lived antidepressant effects in patients with bipolar disorder in small controlled trials, under a maintained mood stabiliser and close monitoring, and it is not an approved or established treatment for bipolar disorder anywhere.

This page exists because depression in bipolar disorders is where honest framing matters most. The condition is a routine exclusion in trials and labels, and the switch risk to mania/hypomania is considered in clinical protocols. Moreover, people with bipolar disorders may have been told that "antidepressants failed you" without the full picture of why.

What the trials actually did

The strongest controlled evidence comes from two small randomised, double-blind, placebo-controlled crossover trials conducted at the US National Institute of Mental Health (NIMH). Together, these studies evaluated 32 patients with treatment-resistant bipolar I or bipolar II depression, all of whom continued therapeutic lithium or valproate while receiving intravenous ketamine (0.5 mg/kg) or saline placebo.

Both studies demonstrated rapid antidepressant effects, with improvements in depressive symptoms detectable within 40 minutes and significant differences from placebo observed during the first several days. However, the effects were generally transient, with the strongest evidence of benefit occurring within the first week rather than demonstrating sustained improvement over two weeks (Diazgranados et al., 2010; Zarate et al., 2012).

Subsequent small open-label and observational studies have investigated repeated ketamine infusions and intranasal esketamine in bipolar depression. Systematic reviews and meta-analyses have brought these findings together, suggesting potential antidepressant benefits while highlighting substantial limitations in sample size, study design, treatment protocols and follow-up duration. Pooling studies increases the amount of available data but does not overcome the methodological limitations of the underlying research (McIntyre et al. 2020; Nunez et al., 2023).

Why the study design matters: participants in the original controlled trials remained on lithium or valproate and underwent close clinical monitoring. These findings therefore support the potential for rapid, short-term antidepressant effects when ketamine is administered alongside established mood-stabilising treatment.

They do not establish whether ketamine is effective or safe without concurrent mood stabilisation, whether repeated treatment produces sustained benefits, or what the longer-term risks of treatment-emergent mania or hypomania might be. Importantly, the trials were not designed to determine whether lithium or valproate specifically protects against mood switching during ketamine treatment.

The risk of switching to mania or hypomania

Treating bipolar depression requires particular care because some antidepressant treatments can precipitate a switch from depression into hypomania or mania. This phenomenon, known as treatment-emergent affective switching, is well recognised with certain conventional antidepressants. However, the risk varies according to the treatment, bipolar subtype, history of manic episodes and presence of mixed features. Whether ketamine independently increases this risk, and to what extent, remains uncertain.

In the original ketamine crossover trials, treatment-emergent mania or hypomania was uncommon. Participants continued taking lithium or valproate and were closely monitored throughout treatment. A 2023 systematic review and meta-analysis of ketamine and esketamine in bipolar depression reported a switch rate of approximately 2.4% across included studies (Nunez et al., 2023). Importantly, this is a pooled descriptive estimate from heterogeneous, relatively small studies, not a reliable individual prediction of risk or proof of safety.

These findings should not be interpreted as evidence that ketamine carries no risk of inducing mania or hypomania. Nor do the studies establish that concurrent mood stabilisers specifically prevent switching. The safety of repeated ketamine administration, particularly over longer treatment periods, remains insufficiently characterised in bipolar disorder.

For anyone with bipolar disorder considering ketamine treatment, appropriate clinical safeguards should include:

• Specialist psychiatric assessment: confirm the bipolar diagnosis and subtype, assess current mood symptoms and mixed features, and review any history of treatment-emergent mania or hypomania.
• Review of mood-stabilising treatment: assess current medications, adherence and adequacy of mood stabilisation. The original controlled trials were conducted in patients maintained on lithium or valproate, so their findings cannot automatically be generalised to patients receiving ketamine without these medications.
• Ongoing monitoring and a clear management plan: establish procedures for identifying emerging hypomanic or manic symptoms, including reduced need for sleep, increased energy, impulsivity or unusual changes in behaviour, and specify how treatment would be reassessed if these symptoms develop.

Ketamine treatment for bipolar depression should only be considered within a specialist-led service equipped to provide these safeguards, alongside appropriate medical monitoring.

Screening before treatment is equally important. Some people initially diagnosed with unipolar treatment-resistant depression may have previously unrecognised bipolar disorder, particularly bipolar II, where hypomanic episodes can be overlooked or mistaken for periods of improved functioning.

Before considering ketamine or other interventions for treatment-resistant depression, clinicians should assess for a lifetime history of mania or hypomania, including periods of unusually elevated or irritable mood accompanied by increased energy or activity, reduced need for sleep and changes in behaviour. Assessment should also consider mixed depressive features, family history of bipolar disorder and previous antidepressant-associated mood changes.

If you have experienced recurrent depression but have never been assessed for bipolar disorder, discussing this with your psychiatrist or treating clinician is an important step before pursuing experimental or off-label treatments.

Why the esketamine labels and clinical trials excluded bipolar

Ketamine and esketamine are not specifically licensed for the treatment of bipolar depression in the EU. Their use for this indication would therefore be off-label and requires specialist clinical assessment, informed consent and appropriate monitoring. Esketamine's EU authorisation covers major depressive disorder indications only (treatment-resistant depression with an oral antidepressant, and a short-term psychiatric-emergency indication). Bipolar depression is outside the label, so the reimbursed esketamine pathway that exists for unipolar treatment-resistant depression does not apply.

Most clinical trials investigating ketamine and psychedelics as a treatment for depressive disorders have excluded bipolar disorder, partly for switch-risk management, partly to keep study populations homogeneous. The practical consequence for readers with bipolar diagnoses: the approach of potentially accessing ketamine therapy after "two failed antidepressant treatments" is only for unipolar depression, and the right specialist conversation is a bipolar-specific one.

Established treatments for bipolar depression

Bipolar depression requires a different treatment approach from unipolar depression. Clinical guidelines prioritise treatments that address depressive symptoms while also considering the risk of mania, hypomania and future mood episodes. Conventional antidepressants are generally not recommended as first-line treatment, particularly for bipolar I disorder.

Evidence-based treatment options include:

• Mood-stabilising and antipsychotic medications: quetiapine, lithium, lamotrigine and lurasidone are among the recommended options, with other medications such as cariprazine included in some guidelines. Treatment selection depends on bipolar subtype, symptom severity, previous treatment response and tolerability.
• Medication optimisation and combinations: adjusting existing treatment, including assessing lithium levels where appropriate, or combining medications may improve outcomes when initial treatment is insufficient.
• Electroconvulsive therapy (ECT): an established treatment for severe or treatment-resistant bipolar depression, particularly when a rapid response is needed, such as in cases involving severe suicidality, psychosis or life-threatening deterioration.
• Psychological therapies: structured psychoeducation, cognitive behavioural therapy (CBT), interpersonal and social rhythm therapy (IPSRT), and family-focused therapy can complement medication, supporting symptom management, functioning and relapse prevention.
• Long-term mood stability: maintaining regular sleep and daily routines, recognising early warning signs of mood episodes, and ensuring continuity of psychiatric care are important components of ongoing treatment.

What about conventional antidepressants? Their role in bipolar depression remains more limited and clinically nuanced than in unipolar depression. Antidepressant monotherapy is not recommended for bipolar I depression because of concerns about mood switching and mood destabilisation. In selected patients, antidepressants may be considered alongside mood-stabilising treatment, following careful assessment of bipolar subtype, previous treatment response and risk factors for mania or hypomania.

Before considering ketamine or other off-label interventions, it is worth reviewing whether established treatments have been adequately explored and optimised. Although some specialist guidelines recognise adjunctive ketamine as a third-line option for bipolar depression, evidence for its sustained efficacy and long-term safety remains limited. Treatment decisions should therefore be made collaboratively with a psychiatrist experienced in managing bipolar disorder.

Current clinical trials

Bipolar-specific ketamine and psychedelic trials are not common because of considerations around psychosis risk, but they exist, and registries change. Search ClinicalTrials.gov and CTIS with your diagnosis clearly described, and consult our trials guide for how screening, placebo and consent work. Expect eligibility criteria to be strict about current mood state, stabiliser regimen and monitoring.

Frequently asked questions

Does ketamine work for bipolar depression?

In small crossover trials, a single infusion was added to standard lithium or valproate treatment. Improvements were observed within hours, but the benefits were generally short-lived, with the strongest evidence supporting effects over the first several days. Although these findings are promising, larger studies are needed to establish the effectiveness and safety of repeated treatment and whether benefits can be sustained over time.

Can ketamine trigger mania?

Potentially, although the extent of this risk remains uncertain. Some antidepressant treatments can precipitate mania or hypomania in people with bipolar disorder, but the risk varies by treatment and individual clinical factors. In small ketamine trials, treatment-emergent mood switching was uncommon, particularly among participants receiving ongoing mood-stabilising medication. However, the available evidence is insufficient to establish reliable risk estimates or determine whether concurrent mood stabilisers specifically prevent switching. Careful psychiatric assessment, monitoring during and after treatment, and a clear plan for managing emerging manic or hypomanic symptoms are therefore essential.

Can I access esketamine (Spravato) for bipolar depression?

Esketamine is not currently authorised in the European Union specifically for bipolar depression. Prescribing outside it would be off-label medicine for a prescriber to justify, not a pathway this site can map.

What should I discuss with my psychiatrist?

Ask whether your current treatment reflects evidence-based recommendations for your specific bipolar diagnosis, including options such as quetiapine, lithium, lamotrigine, lurasidone or appropriate medication combinations. It is also worth reviewing whether previous treatments were given at adequate doses and durations, and whether your history has been thoroughly assessed for manic or hypomanic episodes and mixed features.

Beyond managing your current depressive symptoms, discuss a longer-term plan for maintaining mood stability, recognising early warning signs of relapse and deciding what treatment options may be appropriate if established approaches have not provided sufficient benefit. If ketamine is being considered, ask about the strength of the evidence, potential risks, monitoring procedures and realistic expectations for treatment outcomes.

Sources

1. Diazgranados et al. (2010), Archives of General Psychiatry — ketamine add-on in treatment-resistant bipolar depression, crossover RCT
2. Zarate et al. (2012), Biological Psychiatry — replication crossover RCT, ketamine add-on in bipolar depression
3. Nunez et al. (2023), Brain Sciences — systematic review and meta-analysis: ketamine and esketamine in bipolar depression, incl. pooled switch estimate
4. McIntyre et al. (2020), American Journal of Psychiatry — synthesis on ketamine/esketamine, including bipolar data and switch reporting
5. EMA — Spravato product information (licensed indications)
6. NICE CG185 — bipolar disorder: assessment and management
7. DGBS/AWMF S3-Leitlinie Bipolare Störungen

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Bipolar disorder decisions belong with a psychiatrist who knows your full history. If you are in crisis, contact your local emergency number (112 in the EU) or a crisis line immediately.